Print

WHO signs MoU with International Generic and Biosimilar Medicines Association to promote access (October 2019)

Full access to medicines is hampered by a variety of factors. Two important barriers are high prices and regulatory issues such as long lag times in bringing medicines to market.

Print

IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)

IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)

Print

The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)

The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

c/o Interexperts SA
Rue des Pierres-du-Niton 17
1207 Geneva, Switzerland

Telephone: +32 (0)2 5346607
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or 
This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site